Siegfried Holding
Market Cap
CHF3.3b
Last Updated
2021/04/09 17:04 UTC
Data Sources
Company Financials +
Executive Summary
Siegfried Holding AG engages in the life sciences business worldwide. More Details
Rewards
Risk Analysis
No risks detected for SFZN from our risk checks.
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Siegfried Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SFZN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: SFZN's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-0.6%
SFZN
2.0%
CH Life Sciences
0.8%
CH Market
1 Year Return
83.8%
SFZN
64.7%
CH Life Sciences
21.0%
CH Market
Return vs Industry: SFZN exceeded the Swiss Life Sciences industry which returned 64.7% over the past year.
Return vs Market: SFZN exceeded the Swiss Market which returned 21% over the past year.
Shareholder returns
| SFZN | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.6% | 2.0% | 0.8% |
| 30 Day | 8.1% | 6.5% | 3.3% |
| 90 Day | 18.2% | 7.5% | 5.3% |
| 1 Year | 85.0%83.8% | 65.4%64.7% | 24.7%21.0% |
| 3 Year | 140.8%136.0% | 164.4%158.5% | 35.0%19.0% |
| 5 Year | 337.3%321.3% | 288.8%263.5% | 60.7%31.6% |
Long-Term Price Volatility Vs. Market
How volatile is Siegfried Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Do Its Financials Have Any Role To Play In Driving Siegfried Holding AG's (VTX:SFZN) Stock Up Recently?2 weeks ago | Simply Wall St
What Kind Of Shareholders Hold The Majority In Siegfried Holding AG's (VTX:SFZN) Shares?1 month ago | Simply Wall St
Is Siegfried Holding (VTX:SFZN) A Risky Investment?Valuation
Is Siegfried Holding undervalued compared to its fair value and its price relative to the market?
53.19x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SFZN (CHF781) is trading above our estimate of fair value (CHF602.94)
Significantly Below Fair Value: SFZN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SFZN is poor value based on its PE Ratio (53.2x) compared to the XE Life Sciences industry average (52.2x).
PE vs Market: SFZN is poor value based on its PE Ratio (53.2x) compared to the Swiss market (24.9x).
Price to Earnings Growth Ratio
PEG Ratio: SFZN is poor value based on its PEG Ratio (2.3x)
Price to Book Ratio
PB vs Industry: SFZN is good value based on its PB Ratio (4.5x) compared to the XE Life Sciences industry average (5.9x).
Future Growth
How is Siegfried Holding forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
23.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SFZN's forecast earnings growth (23.4% per year) is above the savings rate (-0.3%).
Earnings vs Market: SFZN's earnings (23.4% per year) are forecast to grow faster than the Swiss market (13.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SFZN's revenue (8.4% per year) is forecast to grow faster than the Swiss market (4.5% per year).
High Growth Revenue: SFZN's revenue (8.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SFZN's Return on Equity is forecast to be low in 3 years time (15.1%).
Past Performance
How has Siegfried Holding performed over the past 5 years?
11.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SFZN has high quality earnings.
Growing Profit Margin: SFZN's current net profit margins (7.2%) are higher than last year (6.4%).
Past Earnings Growth Analysis
Earnings Trend: SFZN's earnings have grown by 11.8% per year over the past 5 years.
Accelerating Growth: SFZN's earnings growth over the past year (14.6%) exceeds its 5-year average (11.8% per year).
Earnings vs Industry: SFZN earnings growth over the past year (14.6%) underperformed the Life Sciences industry 43.9%.
Return on Equity
High ROE: SFZN's Return on Equity (8.3%) is considered low.
Financial Health
How is Siegfried Holding's financial position?
Financial Position Analysis
Short Term Liabilities: SFZN's short term assets (CHF651.0M) exceed its short term liabilities (CHF193.6M).
Long Term Liabilities: SFZN's short term assets (CHF651.0M) exceed its long term liabilities (CHF315.5M).
Debt to Equity History and Analysis
Debt Level: SFZN's debt to equity ratio (19.1%) is considered satisfactory.
Reducing Debt: SFZN's debt to equity ratio has reduced from 45.7% to 19.1% over the past 5 years.
Debt Coverage: SFZN's debt is well covered by operating cash flow (82%).
Interest Coverage: SFZN's interest payments on its debt are well covered by EBIT (31.6x coverage).
Balance Sheet
Dividend
What is Siegfried Holding current dividend yield, its reliability and sustainability?
0.38%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: SFZN's dividend (0.38%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.51%).
High Dividend: SFZN's dividend (0.38%) is low compared to the top 25% of dividend payers in the Swiss market (3.49%).
Stability and Growth of Payments
Stable Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: SFZN is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: SFZN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SFZN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Wolfgang Wienand (48 yo)
2.25yrs
Tenure
Dr. Wolfgang Wienand has been Chief Executive Officer at Siegfried Holding AG since January 01, 2019. Dr. Wienand has been President and Chief Executive Officer since January 2019 at Siegfried AG. Dr. Wien...
Leadership Team
Experienced Management: SFZN's management team is considered experienced (2.3 years average tenure).
Board Members
Experienced Board: SFZN's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Siegfried Holding AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Siegfried Holding AG
- Ticker: SFZN
- Exchange: SWX
- Founded: 1873
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF3.251b
- Shares outstanding: 4.18m
- Website: https://www.siegfried.ch
Number of Employees
Location
- Siegfried Holding AG
- Untere BrUehlstrasse 4
- Zofingen
- Aargau
- 4800
- Switzerland
Listings
Biography
Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, includi...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/09 17:04 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.